Log inSign up
Reading a stock page
  • The tabs show the price chart, results, shareholding, events and news for this one company.
  • The Signal Score sums up trend, momentum and quality from past data. It is a description, not a forecast.
  • Every figure names its source. "Official" means it came from NSE or BSE filings.
  • Use the star to watch the stock, or Add to portfolio to record a trade.

Prices during market hours are delayed by up to 15 minutes. Nothing here is a recommendation to buy or sell.

« Dashboard

MANGALAM ☆ BSE also on NSE

MANGALAM DRUGS & ORGANICS LTD. · code 532637 · INE584F01014 · Pharma & Healthcare · series B · Daily price history

27.54 -1.35 (-4.67%) close on 20 Nov 2026
Official NSE & BSE Auto-Sync: Checking Overview, Financials, Technicals, Shareholding & Events in the background...
24

ISA Signal Score: Poor

Avoid: price and data look unhealthy. Based on prices to 2026-11-20. Confidence 100%.

Trend22
Momentum28
52-week range10
Volume24
Risk31
Fundamentals24

Working for it

  • 50-day average is above the 200-day average

Working against it

  • Price is below its 20-day average
  • Price is below its 50-day average
  • Price is below its 200-day average (long-term weakness)
  • MACD is negative and weakening
  • 55% below its 52-week high
  • More volume on down days than up days (distribution)

Red flags

  • Down 55% from its 52-week high and still weakening
  • Profit fell sharply (729%)
  • Thinly traded: average daily turnover is low, so entering or exiting can be hard

Measured reference levels (not forecasts): 20-day low 27.54, 52-week high 61.80, typical daily move 1.60, two typical moves below price 24.35.

A rule-based reading of price, volume and filed numbers. It is information, not investment advice, and it can be wrong. Do your own research.

At a glance

Five quick readings from results and prices. A starting point for your own research, not advice.
QualityWeakROE -34.9%, ROCE -14.3%, debt 1.10x equity
GrowthSlowSales -14.6% a year over 3 years
ValuationNo earningsP/E cannot be worked out while the company makes a loss.
MomentumWeakBelow its 200-day average, lagged NIFTY 50 by 41.5 points
RiskHighSwings 55% a year, fell up to 51% from a peak, beta 0.51

Smart Investor Tips: MANGALAM

Caution Warranted (Trend or Balance-Sheet Headwinds)

Actionable Insights & Positives

  • Tip: Click the star button above to add this stock to your Watchlist and set a target "Buy below" alert price.

Risk Checks & Things to Verify

  • Deep drawdown (-50.3% from 52-week high). Verify earnings trend and balance-sheet debt before treating a low price as a bargain.
  • Reported a net loss in FY26. Turnaround stories carry higher execution risk.
  • High 30-day annualized volatility (43%). Keep initial position sizes smaller and use wider stop-review levels.

BSE Authentic Bhavcopy & Cross-Exchange Check No API Key

Runs authentic BSE price & volume verification (latest BSE Bhavcopy snapshot, split-adjusted 52W High/Low, 20/50/200 DMA alignment, and 20-day volume trend, plus cross-listed NSE MCP check when shared by ISIN).

Algorithmic Momentum Prediction & Optimal Entry PriceWEAK / REDUCE ON BOUNCES (Score 5/100)

Weak trend, debt overhang, or distribution. Avoid fresh buying until price reclaims 50-DMA (Rs 30.68). If already held, protect capital if it breaks below Rs 22.95 or trim near resistance Rs 31.99.

Optimal Support areaTranche 1 (50%)Tranche 2 (50%)Risk level / ReviewLevel 1 (Swing)Level 2 (Breakout)Risk : Reward
Rs 25.34 – Rs 27.54
Ideal ~Rs 26.44
Rs 27.54 Rs 25.34 Rs 22.95
ATR 5.8%
Rs 32.72 Rs 63.34 1 : 1.8
RSI 41 · Vol 0.60x
1M 3M 6M 1Y 3Y ALL Investment checklist Download CSV 6M change -9.3% · high 38.25 · low 25.70 · max drawdown -24.3%

Live Candlestick & TradingView Chart (MANGALAM)

MARKET CLOSED - EOD SNAPSHOT
Style:  Timeframe:  Overlays:

Key figures results FY26, price 20 Nov

P/E-loss making
P/B0.42xprice / book value
EPSRs -28.05earnings per share
Dividend yield-from saved dividend events
Debt to equity1.10xnet debt Rs 113 Cr
Sales growth-14.6%a year over 3 years
Profit growth-yearly, needs 2+ years
Operating margin-6.9%net margin -19.0%

From the official NSE results filings, consolidated. P/E uses the last full year's EPS. See all years.

Company Debt, Borrowings & Cash Flow Health (Official FY26 Consolidated Filing)

Auto-extracted from official NSE/BSE XBRL Balance Sheet & Cash Flow statements (Rs Crore).

High Debt / Cash Flow Caution · Score 44/100
Total Debt / Loans Rs 113 Cr Increased +Rs 17.0 Cr YoY
Cash & Bank Balances - Liquid cash & equivalents
Net Debt (Loans − Cash) Rs 113 Cr 35.9% of total assets
Debt to Equity & Interest Cover 1.10x D/E Interest cover: -2.1x EBIT
Operating Cash Flow (OCF) Rs 4.00 Cr Cash generated from operations
Free Cash Flow (FCF) - OCF minus Capex
  • Elevated Debt-to-Equity (1.10x).
  • Interest coverage stress (-2.1x) - operating profit barely covers loan interest.
  • High earnings quality: Operating Cash Flow converts 998% of net profit into real cash.

About MANGALAM DRUGS & ORGANICS

Healthcare

No company description saved yet. Use Profile below to read about this company.

Listed on BSE NSE

Market capRs 43.6 CrMicro cap · 1.58 Cr shares
First listed23 May 2005BSE not available · NSE 23 May 2005
Face valueRs 10
Book valueRs 85.79Price is 0.3x book value
ROE0.0%weak, below 8%
ROCE1.7%weak, below 8%

NSE results filing: shares, book value, ROE, ROCE · NSE: listing date, face value · ratios as of FY2024

Profile completeness7 of 8Missing: description · ratios as of FY2024

Checked: BSE 20 Nov 2026. Yahoo Finance did not answer (HTTP 0).

Profile, History and Financial records open a web search for this company in a new tab.

Shareholding

Promoters and group 35.65% 0.00 pp, public 64.35%, as on 30 Sep 2026. Holder names and history

Day range27.00 to 29.03Open 29.03
52-week high55.43 -50.3% from high (20 Nov 2025)
52-week low22.70 +21.3% from low (29 Dec 2025)
Volume6,942 3.6x the 20-day average
RSI (14)39 neutral
Volatility (30d)42.8%annualised
22.70
55.43

Returns

1W-5.1%
1M-8.7%
3M-0.3%
6M-8.2%
1Y-43.0%
YTD-0.2%
3Y a year-34.1%
5Y a year-26.4%

Against the NIFTY 50

PeriodMANGALAMNIFTY 50Difference
1M-8.7%+13.1% -21.8 pts
3M-0.3%+6.4% -6.7 pts
6M-8.2%+8.8% -16.9 pts
1Y-43.0%-1.5% -41.5 pts

Risk over the past year

Volatility55%high
Deepest fall-50.7%from a peak
Beta0.51moves less than the index
Best day+10.0%24 Aug 2026
Worst day-12.4%24 Nov 2025
Up days45%of sessions

Returns use closing prices. Bonus issues and splits are adjusted automatically when detected. Beta compares daily moves with the NIFTY 50 over 246 shared sessions.

AI analysis

Company turnover, products, risks and entry ideas, written by the AI provider you set up in Settings.

Open AI analysis

🛡 Forensic Financial Health: Piotroski F-Score & 3-Step DuPont ROE Decomposition

Institutional balance-sheet quality, earnings-to-cash conversion, and ROE driver breakdown from official XBRL filings.

Piotroski F-Score: 2 / 9 · Weak / Watch Balance Sheet
3-Step DuPont ROE Identity: Leverage-Driven ROE (Watch Debt)
Net Margin: -19.0% × Asset Turnover: 0.74x × Equity Multiplier: 3.06x = ROE -34.9%
⚠ Positive Net Profit (PAT > 0) Rs -44.0 Cr
✓ Positive Operating Cash Flow (OCF > 0) Rs 4.00 Cr
⚠ High Cash Conversion (OCF >= 85% of PAT) N/A
⚠ Improving Return on Assets (ROA YoY) -14.0% vs 1.9%
⚠ Conservative / Decreasing Debt-to-Equity 1.10x (prev 0.64x)
✓ Healthy Balance Sheet Asset Coverage 3.18x
⚠ Institutional Return on Equity (ROE >= 14%) -34.9%
⚠ Stable / Expanding Profit Margin YoY -19.0% vs 2.2%
⚠ Asset Turnover Efficiency (Sales / Assets) 0.74x

Quarterly Results (Last 8 Quarters — QoQ & YoY Acceleration) Rs crore

Rs crore Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales / Revenue 88.772.857.249.558.467.357.179.4
Sales QoQ % +11.0%-18.0%-21.4%-13.4%+17.8%+15.3%-15.1%+39.0%
Operating Profit 8.779.90-4.62-2.84-1.54-5.620.91-1.15
Operating Margin (OPM %) 9.9%13.6%-8.1%-5.7%-2.6%-8.4%1.6%-1.4%
Net Profit (PAT) 1.400.06-13.8-7.35-9.84-13.4-7.64-7.21
Profit QoQ % -48.0%-95.7%-23100.0%+46.7%-33.9%-36.4%+43.1%+5.6%
Profit YoY % +180.0%-98.3%-614.9%-373.2%-802.9%-22466.7%+44.6%+1.9%
Net Margin % 1.6%0.1%-24.1%-14.8%-16.9%-19.9%-13.4%-9.1%

Sales and profit Rs crore, consolidated

Sales growth-14.6%a year, 3Y
Profit growth-a year, 3Y
EPS growth-a year, 3Y
Avg ROE-7.3%4 years

Profit and loss

Rs croreFY23*FY24FY25FY26
Sales372369318232
Sales growth--1.0%-13.7%-27.0%
Operating profit25.517.436.0-16.0
Operating margin6.9%4.7%11.3%-6.9%
Other income0.440.101.001.00
Interest12.813.915.016.0
Depreciation11.014.717.018.0
Profit before tax2.21-11.15.00-49.0
Tax rate42.5%--41.0%-
Net profit1.2707.00-44.0
Profit growth--100.0%--728.6%
Net margin0.3%0.0%2.2%-19.0%
EPS (Rs)0.80-5.734.25-28.05

Balance sheet

Rs croreFY23*FY24FY25FY26
Equity (net worth)152136149103
Borrowings68.388.096.0113
Cash2.690.91--
Total assets360333366315
Debt to equity0.45x0.65x0.64x1.10x

Debt, Loans, Cash Flow & Working Capital

Rs croreFY23*FY24FY25FY26
Operating Cash Flow (OCF)39.5-11.143.04.00
Capital Expenditure (Capex)27.90--
Free Cash Flow (FCF = OCF - Capex)11.6-11.1--
OCF / Net Profit Conversion31.12x-6.14x-
Total Borrowings / Loans68.388.096.0113
Cash & Bank Balances2.690.91--
Trade Receivables (Cr)46.527.9--
Receivable Days45.62x27.67x--
Inventories (Cr)137124--
Inventory Days134.79x122.44x--

Returns on capital

Rs croreFY23*FY24FY25FY26
ROE0.8%0.0%4.9%-34.9%
ROCE7.7%1.6%9.6%-14.3%
Interest cover1.17x0.20x1.33x-2.06x

Read from the official annual results filed with NSE (XBRL), consolidated figures; years marked * are on the other basis because only that file was readable. ROE uses average equity of the year and the year before when both are saved, ROCE uses profit before interest and tax over total assets less current liabilities. EPS is per today's share. More years are loading and will appear on a later visit. Check the annual report before investing.

Compared with its sector Pharma & Healthcare

StockPriceDay1 yearMkt cap (Cr)P/EP/BROENet margin
LAURUSLABSLaurus Labs Limited 2,295.00 -0.3% - 123,689 139.4 23.3 16.8% 13.1%
ZYDUSLIFEZydus Lifesciences Limited 1,195.05 -0.4% - 120,222 31.3 6.1 0.6% 0.6%
MANKINDMankind Pharma Limited 2,660.00 +1.1% - 106,556 55.7 11.4 20.4% 18.5%
MAXHEALTHMax Healthcare Institute Limit 1,079.60 +4.0% - 104,927 72.8 9.8 13.4% 17.2%
LUPINLUPIN LTD. 2,010.00 +0.6% - 91,596 17.2 - 13.4% 19.2%
GLENMARKGLENMARK PHARMACEUTICALS LTD. 2,648.00 +1.0% - 74,724 - 9.5 -19.1% -12.7%
FORTISFORTIS HEALTHCARE LTD. 825.00 +2.0% - 62,284 59.8 - 7.8% 11.7%
GLANDGland Pharma Limited 3,331.35 +1.2% - 54,871 53.4 - 8.9% 16.0%
IPCALABIPCA LABORATORIES LTD. 1,845.05 -0.8% - 46,809 41.0 5.8 14.7% 12.3%
GLAXOGLAXOSMITHKLINE PHARMACEUTICAL 2,732.50 +0.7% - 46,291 78.5 26.0 33.2% 17.1%
EMCUREEmcure Pharmaceuticals Limited 2,336.05 -0.4% - 44,317 47.9 9.0 19.0% 10.2%
MEDANTAGlobal Health Limited 1,481.30 +0.2% - 39,774 71.5 - 16.5% 12.6%
Sector median- 50.27.214.2%

The 12 largest of 80 stocks in this sector on BSE, by market cap where known and traded value otherwise. Valuation shows for stocks whose results this site has read; it fills in as people open more stock pages. Prices from 20 Nov 2026.

Today: 15 minute chart and signal

Opens when you view this tab.

Analysis and next-session reading

Opens when you view this tab.

Complete analysis report Financials, shareholding, events, risks and a data reliability score.

Signals

Price is below its 50-day average 20-day average is below the 50-day (short-term downtrend) Price is below its 200-day average (long-term downtrend) RSI 39: neutral Volume is 3.6x the 20-day average

Simple rules applied to end-of-day prices. They describe what the chart is doing and are not advice to buy or sell.

When is a good price? from this stock's own price history

The price is in the lower quarter of its 1-year range and is lower than it was on 81% of days in the past year.

Support (prices below today's)

20-day low27.00-2.0%
60-day low27.00-2.0%
52-week low22.70-17.6%

Resistance (prices above today's)

200-day average30.01+9.0%
50-day average30.68+11.4%
20-day high31.99+16.2%
60-day high38.25+38.9%

Zones buyers often watch

Lower quarter of the 1-year range 22.70 to 30.88 price is inside this zone now
Pullback of 10% to 20% from the high 44.34 to 49.89 A common area for dips inside an uptrend.
Around the 200-day average 29.11 to 30.91 Long-term trend line, often watched as support.

Deepest fall from a peak in the past year: -50.7%. Currently -47.0% below its latest peak. Levels are from history and do not predict where the price will go.

Moving averages and momentum

IndicatorValueReading
20-day average29.00 Price is 5.0% below
50-day average30.68 Price is 10.2% below
200-day average30.01 Price is 8.2% below
RSI (14)39Neutral
MACD (12, 26, 9)-0.53Below its signal line (momentum fading)
Volatility (30d)42.8%Medium yearly swings

Support and resistance

R229.89
R128.71
Pivot27.86
S126.68
S225.83

Classic pivot levels from the latest session's high, low and close. Prices often pause near them, but they are only reference points.

DateOpenHighLow CloseChangeVolume
2026-11-20 29.03 29.03 27.00 27.54 -4.67% 6,942
2026-11-19 28.67 28.97 28.06 28.89 +0.77% 496
2026-11-18 28.34 28.75 28.28 28.67 -3.24% 3,897
2026-11-17 28.85 29.63 28.42 29.63 +5.15% 2,477
2026-11-16 29.03 29.03 28.03 28.18 -2.93% 3,477
2026-11-13 29.46 29.69 28.84 29.03 -0.24% 406
2026-11-12 31.99 31.99 29.10 29.10 -0.95% 2,618
2026-11-11 29.30 30.15 28.62 29.38 +0.27% 3,116
2026-11-09 29.10 30.10 28.97 29.30 -3.11% 1,706
2026-11-06 30.60 30.60 28.20 29.32 -3.71% 2,591
2026-11-05 30.99 31.56 30.13 30.45 +3.22% 2,535
2026-11-04 29.34 30.83 28.76 29.50 +0.55% 2,372
2026-11-03 29.94 29.94 29.00 29.34 +0.58% 137
2026-11-02 29.06 29.98 28.26 29.17 +0.86% 3,192
2026-10-30 30.17 30.17 28.30 28.92 -3.66% 3,915
2026-10-29 30.03 30.03 29.96 30.02 +4.27% 158
2026-10-28 28.73 29.35 28.46 28.79 +0.21% 381
2026-10-27 29.01 29.50 28.58 28.73 +2.53% 473
2026-10-26 28.09 29.21 27.80 28.02 +0.07% 1,697
2026-10-23 30.20 31.05 28.00 28.00 -5.28% 2,696
2026-10-22 29.80 30.55 29.52 29.56 -1.99% 683
2026-10-21 31.38 31.38 29.88 30.16 -3.89% 916
2026-10-19 31.50 31.50 30.50 31.38 +1.62% 239
2026-10-16 31.63 31.99 30.62 30.88 -2.37% 4,233
2026-10-15 32.32 32.32 30.82 31.63 -1.65% 3,607
2026-10-14 32.43 33.32 31.94 32.16 +1.16% 211
2026-10-13 32.11 32.86 31.75 31.79 +0.35% 270
2026-10-12 31.94 32.47 31.42 31.68 +0.57% 2,415
2026-10-09 32.09 34.00 30.41 31.50 +0.10% 17,308
2026-10-08 33.43 33.43 31.35 31.47 -4.69% 4,605
2026-10-07 31.90 33.88 31.90 33.02 +4.26% 13,727
2026-10-06 29.35 31.99 29.01 31.67 +6.17% 18,548
2026-10-05 29.39 30.10 28.05 29.83 +2.86% 5,098
2026-10-01 31.31 31.31 29.00 29.00 -5.54% 13,795
2026-09-30 30.73 31.96 30.01 30.70 -2.35% 15,432
2026-09-29 30.00 31.98 30.00 31.44 +1.52% 2,926
2026-09-28 31.91 32.94 30.88 30.97 -2.92% 5,301
2026-09-25 31.50 32.51 31.00 31.90 -0.25% 10,513
2026-09-24 32.23 33.00 31.46 31.98 -1.02% 6,676
2026-09-23 32.56 33.92 32.21 32.31 -0.22% 7,271
2026-09-22 33.90 33.90 31.96 32.38 -1.76% 9,133
2026-09-21 34.13 34.60 32.12 32.96 -3.74% 7,915
2026-09-18 34.36 34.99 32.19 34.24 +6.90% 25,385
2026-09-17 31.36 33.84 31.36 32.03 +0.09% 2,904
2026-09-16 33.45 34.00 31.40 32.00 -3.88% 7,346
2026-09-15 36.85 36.87 33.25 33.29 -8.47% 20,433
2026-09-11 35.79 38.25 33.19 36.37 +4.42% 37,817
2026-09-10 32.30 34.83 32.30 34.83 +9.98% 37,614
2026-09-09 29.00 31.80 29.00 31.67 +8.53% 5,256
2026-09-08 29.53 29.84 29.18 29.18 -1.15% 1,073
2026-09-07 29.22 30.54 29.22 29.52 -2.73% 6,536
2026-09-04 29.87 31.16 29.87 30.35 -0.43% 3,995
2026-09-03 31.53 31.53 29.95 30.48 +1.09% 4,545
2026-09-02 29.30 30.85 29.22 30.15 +0.53% 4,611
2026-09-01 31.46 32.15 29.86 29.99 -5.54% 10,419
2026-08-31 31.50 32.29 31.41 31.75 -0.44% 7,725
2026-08-28 32.21 32.42 30.10 31.89 -0.50% 8,289
2026-08-27 30.75 32.78 30.75 32.05 +1.97% 23,286
2026-08-26 33.72 33.72 31.13 31.43 -4.73% 18,754
2026-08-25 30.56 33.30 30.03 32.99 +8.59% 35,370
2026-08-24 27.34 30.38 27.34 30.38 +9.99% 28,675
2026-08-21 27.20 27.99 27.00 27.62 +3.21% 3,018
2026-08-20 27.50 27.50 26.56 26.76 -0.89% 4,479
2026-08-19 28.00 28.30 26.61 27.00 -3.57% 5,112
2026-08-18 28.79 28.79 27.94 28.00 +0.18% 1,607
2026-08-17 28.45 29.29 27.48 27.95 -1.76% 984
2026-08-14 29.00 29.49 28.00 28.45 +5.53% 7,343
2026-08-13 27.40 28.07 26.55 26.96 -0.48% 10,437
2026-08-12 27.00 27.43 26.90 27.09 +0.33% 1,060
2026-08-11 27.14 27.33 26.96 27.00 -0.04% 763
2026-08-10 27.69 27.78 26.74 27.01 -0.04% 3,837
2026-08-07 27.50 27.63 27.01 27.02 +0.60% 2,727
2026-08-06 26.87 27.40 26.75 26.86 -0.41% 3,439
2026-08-05 27.16 27.50 26.86 26.97 -1.46% 837
2026-08-04 25.70 27.43 25.70 27.37 +1.37% 1,313
2026-08-03 27.01 27.50 26.90 27.00 -1.75% 17,939
2026-07-31 27.03 27.58 27.02 27.48 +1.66% 2,009
2026-07-30 27.35 27.53 26.92 27.03 -0.84% 1,827
2026-07-29 27.00 27.34 26.67 27.26 +0.96% 6,666
2026-07-28 27.00 27.55 26.90 27.00 -1.82% 1,070
2026-07-27 26.90 27.58 26.90 27.50 +1.74% 399
2026-07-24 26.77 27.59 26.77 27.03 -1.06% 3,154
2026-07-23 27.09 27.71 27.09 27.32 +0.85% 3,908
2026-07-22 28.50 28.50 27.03 27.09 -0.33% 1,236
2026-07-21 27.24 27.62 27.05 27.18 -0.22% 1,128
2026-07-20 27.60 27.80 27.21 27.24 -1.59% 4,354
2026-07-17 27.55 27.96 26.95 27.68 +0.51% 8,037
2026-07-16 29.00 29.00 27.09 27.54 -1.75% 20,937
2026-07-15 28.30 28.35 27.52 28.03 +1.67% 8,532
2026-07-14 29.00 29.00 27.30 27.57 -1.47% 6,135
2026-07-13 28.89 28.89 27.25 27.98 -0.07% 4,549
2026-07-10 27.90 28.50 27.53 28.00 +3.09% 2,456
2026-07-09 27.12 28.00 27.01 27.16 +0.15% 10,413
2026-07-08 27.65 28.31 27.00 27.12 -3.18% 6,060
2026-07-07 28.50 28.59 27.80 28.01 -2.30% 4,018
2026-07-06 28.39 28.87 28.00 28.67 +0.99% 8,566
2026-07-03 28.40 28.94 27.61 28.39 +0.67% 6,974
2026-07-02 28.78 28.78 28.16 28.20 -0.07% 2,475
2026-07-01 28.52 29.07 28.11 28.22 -1.05% 1,770
2026-06-30 28.40 29.27 28.05 28.52 +0.46% 2,196
2026-06-29 28.81 29.12 27.91 28.39 -1.08% 2,663
2026-06-25 29.00 30.27 28.61 28.70 -1.17% 3,013
2026-06-24 28.22 30.00 28.22 29.04 -2.22% 1,386
2026-06-23 29.53 30.50 29.50 29.70 -0.80% 3,363
2026-06-22 30.49 30.49 29.25 29.94 -0.70% 10,806
2026-06-19 30.00 30.25 29.36 30.15 +0.27% 6,903
2026-06-18 30.24 30.48 29.50 30.07 -0.66% 2,320
2026-06-17 30.18 30.55 29.58 30.27 +0.30% 6,082
2026-06-16 30.10 30.18 29.01 30.18 +2.27% 3,488
2026-06-15 28.46 29.51 28.18 29.51 +4.98% 4,172
2026-06-12 28.99 28.99 27.78 28.11 +0.39% 3,869
2026-06-11 28.57 29.39 27.84 28.00 -0.04% 2,727
2026-06-10 29.60 29.60 28.01 28.01 -0.71% 5,514
2026-06-09 28.74 29.24 28.00 28.21 -1.84% 3,611
2026-06-08 28.30 29.76 27.97 28.74 +1.38% 14,108
2026-06-05 28.60 29.39 28.30 28.35 -1.22% 3,762
2026-06-04 28.50 29.37 28.00 28.70 +0.00% 1,940
2026-06-03 27.25 28.96 27.25 28.70 +0.74% 5,811
2026-06-02 28.05 28.99 28.05 28.49 -2.96% 1,949
2026-06-01 29.16 30.29 28.12 29.36 +1.77% 5,285
2026-05-29 28.25 29.24 28.25 28.85 -0.17% 3,424
2026-05-27 28.95 29.67 28.60 28.90 -0.17% 4,599
2026-05-26 28.60 30.00 28.60 28.95 -0.75% 6,437
2026-05-25 29.30 30.80 29.00 29.17 -2.73% 21,931
2026-05-22 29.38 30.89 29.38 29.99 -1.61% 855
2026-05-21 30.80 31.94 29.56 30.48 -0.29% 1,325
2026-05-20 28.90 31.15 28.90 30.57 +2.41% 11,040
2026-05-19 30.00 30.39 29.40 29.85 -1.74% 664
2026-05-18 28.98 30.49 28.52 30.38 +1.23% 8,257

News from the last 15 days More

Shareholding pattern

Up to dateNSE listingChecks passed

Quarter ended 30 Sep 2026, filed 15 Oct 2026. Latest filing is for the expected quarter (Sep 2026). Company: MANGALAM DRUG & CHEM LTD, ISIN INE584F01014.

Promoters and group
35.65%
0.00 pp vs Jun 2026
Public (all, Category B)
64.35%
0.00 pp vs Jun 2026

Foreign, domestic institution and mutual fund lines need the filing file for the period. An admin can load them under Admin > Shareholding tracker.

Ownership split

Trend

Latest quarter compared

CategoryPrevious (Jun 26)Latest (Sep 26)Change (pp)Change in sharesYear earlier (pp)What it may mean
Promoters and group35.65%35.65%0.00 pp--14.65 ppNo material change.
Public (all, Category B)64.35%64.35%0.00 pp-+14.65 ppNo material change.

Change is in percentage points (latest percent minus previous percent), not a relative change. Mutual funds and insurers are part of domestic institutions and are never added to it. Only comparable quarters (1 to 6 months apart; about a year for the year-earlier column) are compared.

Insights and risk alerts

No rule was triggered by the data in the database. That is not a clean bill of health: the rules look only at reported holdings.

These alerts describe reported ownership. They are not buy or sell advice. Judge the company with its results, debt, valuation and announcements.

Who holds the shares

The exchange listing has no filing file for this stock, so holder names are not available.

Quarter by quarter

Quarter endedPromotersChangePublicChangeFiledSource
Sep 202635.65%0.00 pp64.35%0.00 pp15 Oct 2026NSE
Jun 202635.65%0.00 pp64.35%0.00 pp10 Jul 2026NSE
Mar 202635.65%+0.01 pp64.35%-0.01 pp17 Apr 2026NSE
Dec 202535.64%-14.66 pp64.36%+14.66 pp19 Jan 2026NSE
Sep 202550.30%0.00 pp49.70%0.00 pp16 Oct 2025NSE
Jun 202550.30%0.00 pp49.70%0.00 pp18 Jul 2025NSE
Mar 202550.30%0.00 pp49.70%0.00 pp17 Apr 2025NSE
Dec 2024 revised50.30%0.00 pp49.70%0.00 pp17 Jan 2025NSE
Sep 202450.30%-0.02 pp49.70%+0.02 pp15 Oct 2024NSE
Jun 2024 revised50.32%0.00 pp49.68%0.00 pp09 Jul 2024NSE
Mar 202450.32%0.00 pp49.68%0.00 pp19 Apr 2024NSE
Dec 2023 revised50.32%0.00 pp49.68%0.00 pp19 Jan 2024NSE
Sep 2023 revised50.32%0.00 pp49.68%0.00 pp17 Oct 2023NSE
Jun 202350.32%0.00 pp49.68%0.00 pp20 Jul 2023NSE
Mar 202350.32%0.00 pp49.68%0.00 pp18 Apr 2023NSE
Dec 202250.32%-0.10 pp49.68%+0.10 pp17 Jan 2023NSE
Sep 202250.42%0.00 pp49.58%0.00 pp19 Oct 2022NSE
Jun 202250.42%-0.11 pp49.58%+0.11 pp16 Jul 2022NSE
Mar 202250.53%0.00 pp49.47%0.00 pp18 Apr 2022NSE
Dec 202150.53%0.00 pp49.47%0.00 pp12 Jan 2022NSE
Sep 202150.53%-49.47%-08 Oct 2021NSE
Shareholding details

Loading...

Events

Not checked yet

BSE events come from the BSE corporate actions file, which an admin uploads. There is no automatic BSE fetch. Nothing has been imported for this stock yet.

No events saved for this stock yet.

Fetched from NSE automatically and saved on this site, so past events stay available. Ex date is the first day the stock trades without the benefit; a bonus or split is applied to old prices on its own from that day. Confirm on the exchange website before acting.

ISA shows information and signals worked out from past prices and company filings. They are not recommendations to buy, sell or hold any security, and ISA is not a SEBI-registered investment adviser or research analyst. Prices may be delayed. Check with a registered adviser before you invest.